Market Research Logo

Anca Vasculitis - Pipeline Review, H1 2016

Anca Vasculitis - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Anca Vasculitis - Pipeline Review, H1 2016’, provides an overview of the Anca Vasculitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anca Vasculitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anca Vasculitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Anca Vasculitis
  • The report reviews pipeline therapeutics for Anca Vasculitis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Anca Vasculitis therapeutics and enlists all their major and minor projects
  • The report assesses Anca Vasculitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Anca Vasculitis
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Anca Vasculitis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Anca Vasculitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Anca Vasculitis Overview
Therapeutics Development
Pipeline Products for Anca Vasculitis - Overview
Anca Vasculitis - Therapeutics under Development by Companies
Anca Vasculitis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Anca Vasculitis - Products under Development by Companies
Anca Vasculitis - Companies Involved in Therapeutics Development
ChemoCentryx, Inc.
GlaxoSmithKline Plc
Kineta, Inc.
Anca Vasculitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
belimumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CCX-1378 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CCX-168 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dalazatide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mepolizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Anca Vasculitis - Recent Pipeline Updates
Anca Vasculitis - Dormant Projects
Anca Vasculitis - Product Development Milestones
Featured News & Press Releases
Jan 06, 2016: ChemoCentryx Announces Positive Results in Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168
Nov 09, 2015: Kineta Presents New Data Demonstrating Positive, Predictive Responses to Dalazatide in Psoriasis Patients and in Lupus, ANCA Vasculitis Studies at American College of Rheumatology Annual Meeting
Nov 17, 2014: ChemoCentryx's Orally Administered C5aR Inhibitor CCX168 Shows Benefit In Non-Renal ANCA Vasculitis Disease Activity, In Addition To Previously Shown Kidney Disease Improvements
Jun 02, 2014: ChemoCentryx's Orally-Administered Complement 5a Receptor Inhibitor, CCX168, Shows Benefit in ANCA-Associated Vasculitis Based on Birmingham Vasculitis Activity Score and Renal Disease Measurements
Dec 03, 2013: ChemoCentryx Announces Positive Top-Line CCX168 Phase II Data in ANCA-Associated Renal Vasculitis
Nov 10, 2010: ChemoCentryx Presents Positive Phase I Results For CCX168 At Annual American College Of Rheumatology Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Anca Vasculitis, H1 2016
Number of Products under Development by Companies, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Products under Development by Companies, H1 2016
Anca Vasculitis - Pipeline by ChemoCentryx, Inc., H1 2016
Anca Vasculitis - Pipeline by GlaxoSmithKline Plc, H1 2016
Anca Vasculitis - Pipeline by Kineta, Inc., H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Anca Vasculitis Therapeutics - Recent Pipeline Updates, H1 2016
Anca Vasculitis - Dormant Projects, H1 2016
List of Figures
Number of Products under Development for Anca Vasculitis, H1 2016
Number of Products under Development by Companies, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Targets, H1 2016
Number of Products by Stage and Targets, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Types, H1 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report